DEVELOPMENT OF A QUANTITATIVE ANTIBODY BINDING KIT

生产一套微珠的可行性(简单地说是定量 细胞校准工具包)，它可以与流式细胞仪一起使用 直接量化与特定人群结合的单抗数量 细胞已经被证明。这项建议的目标是 提高QSC微球的结合活性，评价新方法 校准微珠的结合位置，并确定 用这种新方法测量单抗与细胞结合的精密度和准确度 方法论。使用说明书和计算机分析工作表 将被开发来支持该工具包。QSC校准套件和支持 材料将由三名外部调查人员进行初步评估， 然后通过研讨会和样本进行更全面的评估 在南卡罗来纳州查尔斯顿举行的临床细胞计数会议上的分布。这个 这一方法的开发和商业化将为临床提供 拥有强大而创新的诊断工具的研究实验室。 能够快速准确地确定单抗的结合量 特定的细胞群将有助于病理学家、免疫学家和 肿瘤学家实现更准确的诊断、治疗和预后 免疫相关疾病，如艾滋病。

The feasibility of producing a set of microbeads (Quantitative Simply Cellular Calibration Kit) which can be used with a flow cytometer to directly quantitate the number of mAbs binding to specific populations of cells has been demonstrated. The objectives of this proposal are to improve the binding reactivity of the QSC microbeads, evaluate new methods of calibrating the binding sites of the microbeads and determine the precision and accuracy of measuring mABs binding to cells by this new methodology. An instruction manual and computerized analysis worksheet will be developed to support this kit. The QSC Calibration Kit and support materials will be initially evaluated by three outside investigators, followed by a more general evaluation via a workshop and sample distribution at the Clinical Cytometry Meeting in Charleston, SC. The development and commercialization of this methodology will provide clinical and research laboratories with a powerful and innovative diagnostic tool. Being able to quickly and accurately determine the number of mAbs binding to specific cell populations will help pathologists, immunologists and oncologists to achieve more accurate diagnosis, treatment and prognosis of immune related diseases, such as AIDS.